High efficacy and good safety profile for the R21/Matrix-M malaria vaccine in African children

Phase III trial results of the R21/Matrix-M vaccine developed by Oxford University and Serum Institute of India Pvt Ltd, leveraging Novavax’s Matrix-M adjuvant, has confirmed high efficacy and supported regulatory approvals and licensure in several African countries.

Leave A Comment

Your email address will not be published. Required fields are marked *